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Background: Despite growing interest and urges by leading experts for the routine collection of patient reported
outcome (PRO) measures in all general care patients, and in particular cancer patients, there has not been an
updated comprehensive review of the evidence regarding the impact of adopting such a strategy on patients,
service providers and organisations in an oncologic setting.
Methods: Based on a critical analysis of the three most recent systematic reviews, the current systematic review
developed a six-method strategy in searching and reviewing the most relevant quantitative studies between
January 2000 and October 2011 using a set of pre-determined inclusion criteria and theory-based outcome
indicators. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system was used
to rate the quality and importance of the identified publications, and the synthesis of the evidence was conducted.
Results: The 27 identified studies showed strong evidence that the well-implemented PROs improved patient-
provider communication and patient satisfaction. There was also growing evidence that it improved the monitoring
of treatment response and the detection of unrecognised problems. However, there was a weak or non-existent
evidence-base regarding the impact on changes to patient management and improved health outcomes, changes
to patient health behaviour, the effectiveness of quality improvement of organisations, and on transparency,
accountability, public reporting activities, and performance of the health care system.
Conclusions: Despite the existence of significant gaps in the evidence-base, there is growing evidence in support
of routine PRO collection in enabling better and patient-centred care in cancer settings.
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Patient reported outcome (PRO) measures include
health status assessments and measures for health-
related quality-of-life (HRQOL), symptom reporting,
satisfaction with care, treatment satisfaction, economic
impact, and specific dimensions of patient experience
such as depression and anxiety [1]. The USA Food and
Drug Agency (FDA) adopts a much broader definition
[2] as “A PRO is any report coming directly from patients* Correspondence: jackchen@unsw.edu.au
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reproduction in any medium, provided the orabout a health condition and its treatment”, meaning
that PROs capture patients’ perspectives about how ill-
ness or new therapies impact on their general well-being
. There is a growing interest from clinicians, researchers,
industry and policy-makers in routinely collecting PROs
to facilitate timely, patient-centred and evidence-based
care. For example, the National Health Service (NHS) of
the UK has been implementing a world-leading initiative
for the routine collection of PROs that firstly included
a few selected elective surgeries (e.g. unilateral
hip replacements, unilateral knee replacements, groin
hernia surgery or varicose vein surgery) [3] but are soon
expanding to many other conditions such as mastectomytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Patient-Reported Outcomes Measurement Information
System (PROMIS), a National Institutes of Health
funded initiative starting in 2004, is providing a publicly
available web-based resource that can be used to meas-
ure key health symptoms and HRQOL [4]. The trad-
itional paper-based PROs instruments are limited by its
lack of flexibility, language and literacy requirement,
[5,6] possible inappropriateness towards minority
groups, [7,8] lack of timeliness (in generating instantan-
eous clinical meaningful interpretations) [9] and inability
to adopt state-of-the-art measurement science such as
Item Response Theory (IRT) and Computer Adapted
Test (CAT) technique [10]. To overcome the difficulty
of integrating the administration and analysis of PRO in-
struments into clinical practice, researchers are develop-
ing and validating alternatives to traditional paper-
based instruments such as office-based touch-screen
computers, [11-13] telephone-based interactive voice-
response (IVR) systems, [14-16] hand-held computers,
[17,18] mobile phones, [19-21] and more recently, the
Internet [22-24]. Some rationales [25-28] put forward
for measuring PROs in a cancer setting include, but not
limited to: 1) better communication and shared decision
making by patients and providers; 2) assessing the health
status of patients entering therapy and identifying treat-
able problems; 3) determining the degree and sources
of the patient’s decreased ability to function; 4)
distinguishing between types of problems, including
physical, emotional, and social; 5) detecting adverse ef-
fects of therapy; 6) monitoring the effects of disease pro-
gression and response to therapy; 7) informing decisions
about changing treatment plans, and 8) predicting the
course of disease and outcomes of care.
However, despite growing interest and urges by the lead-
ing experts for applying routinely collected PROs for all
cancer patients, there has not been an updated compre-
hensive review of the evidence regarding the impact of
adopting such a strategy on patients, services providers
and organisations. The most recent review focused only
on clinical trial design [26] studies of cancer patients, and
only assessed a limited number of outcomes. The current
project aims to provide the much needed comprehensive
review update, including all relevant quantitative studies
investigating the effectiveness of routine PRO collection in
cancer patients. The review research questions were:
1. What are the impacts of composite measures of
PROs collected on cancer patients during treatment
with regards to:
a) Provider behaviour for improving care delivered;
b) Organisational changes within health care settings
for improving processes and models of care
(e.g. targeting and tailoring care);c) Improving clinical outcomes for patients; and
d) Improving patient experience of care (e.g. self-care).
2. What mechanisms are involved in the link between
PROs and the impacts identified in 1(a)?
3. What factors moderate the extent of the impacts
identified in 1(a)?
Methods
Existing systematic reviews and rationale for the current
review
In order to develop an efficient search and review strat-
egy, over 200 existing reviews on the same or similar
topics were firstly systematically examined (identified in
a broad search covering PROs and quality of life mea-
sures between January 2000 and October 2011). Three
reviews [26-28] were identified as the baseline reviews
for this project and their review strategies were carefully
examined in aspects such as the aim and scope, time
span, search strategy and search terms used, articles in-
cluded in each review, and conclusions drawn. A table
summarising the three systematic reviews is presented in
Table 1.
Review search strategy
Analysing the results of above three systematic reviews
demonstrates the importance of search strategies in de-
termining what literature will be included in the study,
which in turn, may influence what conclusions will be
derived. Valderas et al.’s (2008) [27] review excluded
three out of the five clinical trials on cancer patients that
were included in Marshall et al.’s (2006) [28] review.
Lucket et al.’s (2009) review [26] excluded one article
(Taenzer et al. (2000), [33] a before-after study) from
Marshall et al.’s review [27]. A mixed methodology
search was developed in order to maximise the identifi-
cation of recent literature in a short period of time. The
search was conducted in six different ways as follows:
1. A text-based search strategy was developed based on
previous reviews. To elicit previous reviews, a search
was conducted for the text terms ‘patient reported
outcome*’, ‘self-reported’, ‘self-assessed’ anywhere in
title, abstract and key words, combined with ‘quality
of life’, ‘symptom’, ‘functional status’, ‘health status’,
‘patient satisfaction’, ‘unmet need*’ anywhere in title,
abstract and key words. For original articles, a
search was conducted using the same strategy as
above but restricted to those with ‘neoplasm’ or
‘cancer’ in the key words. The search results were
restricted to between January 2000 and October
2011 (full search strategy is listed in Additional file 1:
Appendix 1).
2. All reviews were evaluated (over 200 in total on
various topics but not limited to only cancer
Table 1 A comparison of three baseline reviews
First author,
year





To identify future strategies for (1)
interventions to impact patient
outcomes; and (2) trials to identify
treatment effects.
MEDLINE and PsycINFO were
systematically searched to identify
reports of relevant randomised
controlled trials. The time span was
between 2006 and 1 August 2008.
Four cancer trials were cited in a
previous review (Valderas et al. 2008)
[27].
1. Examined the citations of the four
trials 2. Adopted the strategy used by
Valderas et al. [27] and Espallargues
et al. [29] which involved searching for
the terms ‘health status’, ‘functional
status’ or ‘quality of life’ and ‘clinical
practice’, ‘clinical setting’, ‘practice
setting’, ‘medical practice’ or ‘medical
consultation’ anywhere in the title,
abstract or keywords. Results were
limited by publication date (2006–
2008) and the MeSH or keyword
neoplasm.
6 RCTs Future interventions should motivate
and equip health professionals to use
PROs data in managing patients,
training patients in self-efficacy, using
more specific PROs in clinics,
improving the interpretability of
feedback for both medical staff and
patients, and monitoring the use of
PROs to intervene when problems
arise. Future trials should use a cluster
randomised design to control for




To summarize the best evidence
regarding the impact of providing
patient reported outcomes (PRO)
information to health care
professionals in daily clinical practice.
Systematic review of randomised clinical
trials (Medline, Cochrane Library);
reference lists of previous systematic
reviews; and requests to authors and
experts in the field. Time span: Articles
published between 1978 and 2007.
No exact search terms provided but




original studies; only 2
(not 4) as mentioned in
the above review, are in
an oncologic setting.
Methodological concerns limit the
strength of inference regarding the
impact of providing PROs
information to clinicians. Results
suggest great heterogeneity of
impact; contexts and interventions
that will yield important benefits
remain to be clearly defined.
Marshall et al.
2006 [28]
To synthesize the evidence for using
publically reported performance data
to improve quality. Only articles that
provided empirical evidence on the
impact of public reporting on
outcomes (effectiveness, patient
safety, and patient-centeredness) and
unintended consequences, as well as
selection and quality improvement
activity were included.
Webspirs Medline was searched for
the years from January 1976 to
November 2004. Reference lists of
included studies and appropriate
reviews (Greenhalgh & Meadows 1999
[30]; Espallargues et al. 2000 [29];
Gilbody et al. 2003 [31]) were also
searched for relevant articles. Finally,
PubMed’s ‘related articles’ feature was
used with several background and
included articles (Drury et al. 2000 [32];
Velikova et al. 2004 [13]) to identify
publications with a high proportion of
similar text in the title and abstract.
Terms used in relation to patient-
reported outcome measures (for
example, ‘self report* near2
measure*’) joined with an ‘and’
command to terms related to routine
practice outcomes (for example,
‘improve* near detect*’) or patient
involvement in the health care
process (such as ‘patient* near
provider* near interaction*’).
40 articles included in
the review including 5
publications from an
oncologic setting.
The pattern of results suggests a
general lack of clarity in the field,
especially regarding appropriate goals
for PROs and the mechanisms by
which they might achieve them. To
fully evaluate their role in routine
practice, studies need to use PROs that
capture issues of importance to
patients and to measure impacts
relating to the patient–provider
relationship and patient contributions
to their well-being. Until studies
evaluate PROs as a means to facilitate
patient-centred care, their full potential
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starting point for our top-down and bottom-up search
strategy. We chose the three baseline reviews because
that: 1) they are all systematic reviews that could be
helpful in forming the structure or strategy of the
current review (but not necessarily restricted to cancer
patients); and 2) they were published after 2005.
3. All articles were examined if they cited the 7 key
randomised controlled trials [33-39] listed in the
above reviews (bottom-up approach). References
were also sought from the most recently published
trials, editorials, and commentaries (a top-down
approach). The powerful citation tracking feature of
Scopus™ made this strategy feasible.
4. Simplified text terms (i.e. patient reported outcome,
PRO, PROM, Quality of life, QOL) were used to
conduct a web search for identifying grey literature.
5. Leading researchers and experts in the field (elicited
through the advice of Cancer Institute NSW (CINSW),
editorials, review articles and most cited articles) were
purposefully searched in order to analyse the references
and citations in their publications.
6. Some key cancer centres’ websites were also
searched in order to get more detailed information.
The search was limited to the Scopus™ database as it is
the largest abstract and citation database of peer-reviewed
literature and quality web sources including 100% cover-
age of Medline titles and EBASE. It also tracks, analyses
and visualises publication results, which is well suited to
our top-down and bottom-up search strategy.
Aim, study selection and endpoints of the review
In this review, the aim was to synthesize the evidence in
relation to the impact of routinely collected PROs on pa-
tients, providers, and health organisations. The frame-
works proposed by Greenhalgh and colleagues [25] and by
Abernethy and colleagues [40] were adopted to guide our
evaluation of the existing literature. Greenhalgh et al. [25]
proposed a framework (Figure 1) that depicts mechanisms
between the routine collection of PROs and changes in
patient outcomes. The authors suggest that the multilayer
mediators (i.e. changes to doctor-patient communication,
monitoring treatment responses, detecting unrecognised
problems, changes to patient health behaviour, changes to
clinicians’ management plans, and improved patient satis-
faction) have complex relationships among them. The
studies that revealed these complex relationships may as-
sist in understanding whether and how the underlying
mechanisms of routinely collected PROs work to improve
the intended outcomes.
Recently, Abernethy and colleagues [40] have argued
that the routine collection of PROs has the capacity to
impact not only at the patient-level, but by addressingthe logistics of data linkage, and could ensure that the
system will grow to accommodate other clinical- and
health system-level issues; for example, evaluating com-
parative effectiveness of treatments, monitoring quality
of care, and translating basic science findings into clin-
ical practice (Figure 2). The integration of data systems
will fuel rapid learning cancer care at the national and
societal levels (see Figure 2a and b), making many types
of research and system learning possible across institu-
tions and health sectors. The benefits and implications
of such a rapid learning health care system may include,
but is not limited to, strong and effective quality im-
provement (QI), increased transparency, accountability,
public reporting, better health system performance
(monitoring, planning, financing, evaluating, responding)
and better quality of care.
Combining both frameworks, a list of outcome indica-
tors was developed (Table 2) against which each eligible
study was assessed. To include not only the doctors’ ex-
perience with patients after collecting PROs, but also the
experience of other health services providers (i.e. nurses,
allied health workers), the term ‘Patient-provider commu-
nication’ was used instead of ‘doctor patient communica-
tion’ as proposed by Greenhalgh et al. [25]. In order to
answer review questions 2 & 3 for the studies included, all
possible explicit mediation effects were reviewed through
examining if a path-analysis or a mediation-analysis by
multiple, staged regression approach was presented in the
paper. To examine potential moderating effect, each study
was examined to determine if it explicitly tested the inter-
action effect/moderating effect, or inexplicitly conducted
subgroup analysis. Significant possible mediating or mod-
erating effect results were indicated as part of review end-
points in Table 3. Inferences made and the discussion
were based on these results.
Inclusion and exclusion criteria
The inclusion criteria were: 1) substantial content in pre-
senting empirical evidence on the impact of routinely col-
lected PROs on at least one of the outcomes listed in
Table 2; 2) adult cancer patients; 3) conducted in an onco-
logic setting including inpatient, outpatient and outreach
services; and 4) studies using a composite PRO. We defined
a composite PRO as those PROs are often based on a well-
developed instrument and with an aim for measuring a
substantial aspect of patient conditions (or treatment) with
at least 4 items. To reflect the demanding and complex na-
ture of evaluating the impact of routine collected PROs, eli-
gible studies included a variety of designs including, but not
limited to, randomised controlled trials (RCTs), controlled
before-after trials (CBA) and interrupted time series (ITS).
ITS designs have a longitudinal character, with repeated
measurements and at least three data points before and
after the intervention point. Surveys and clinical audits
B
Evidence: + 
CHANGES TO DOCTOR PATIENT COMMUNICATION 
Clinicians talk to patients about their feelings/health status 
Develop a shared view of treatment goals/health status/reason for the visit 
G
Evidence: - 











CHANGES TO PATIENT 
HEALTH BEHAVIOUR 







Evidence:  - 
CHANGES TO CLINICIAN’S 
MANAGEMENT OF PATIENT 
Changes to/initiation of treatment 
Referrals to other agencies 
Tests to investigate problem further 
Advice on problem management
A
PROVISION OF INFORMATION FROM HEALTH STATUS 
MEASURES TO CLINICIANS 
Alone or supplemented with management guidelines 
With or without training in interpretation of scores 
Fed back once or several times 
Graphical displays of scores or written summaries, with or without 
population norms, with or without previous scores
Figure 1 A hypothetical framework to understand the impact of routinely collected PROs on patient health outcomes (adopted from
Greenhalgh et al. (2005) [25] with permission).
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sults relevant to the listed outcomes.
Studies were excluded if they were non-English lan-
guage articles, opinion and theoretical articles, historical
descriptions, review articles, feasibility studies of some
PROs collection devices, studies investigating childFigure 2 (a) A data linkage framework (b): A learning health care syst
with permission.cancer patients or qualitative studies with no substantial
quantitative results on the review endpoints.
Data extraction and quality assessment
Electronic search results were downloaded into EndNote
bibliographic software. Two reviewers independentlyem. Note: Figures 2: adopted from Aberthnethy et al. (2010) [40]
Table 2 Outcome indicators assessed for each eligible
study included in the review
Number Outcomes
1 Patient-provider communication
2 Monitor treatment response
3 Detect unrecognised problems
4 Changes to patient health behaviour
5 Changes to patient management
6 Improved patient satisfaction
7 Improved health outcomes
8 Strong & effective quality improvement
9 Increased transparency, accountability, public reporting
10 Better system performance (monitoring, planning, financing;
evaluating, responding)
11 Mediating variables on the effect (both at individual and
organisation level)
12 Possible subgroup effects
Note: Both 11 & 12 are combined in the summarising tables as few studies
have explored such issues.
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http://www.biomedcentral.com/1472-6963/13/211(JC, LO) screened all titles and abstracts of citations
identified by the electronic search, applied the selection
criteria to potentially relevant papers, and extracted data
from included studies using a standardised form. Any
disagreements concerning studies to be included were
resolved by consensus.
All studies were classified into two domains. Domain 1
correlated sample characteristics with population wide
characteristics, and Domain 2 focused on study design.
The data extraction form was adapted from other review
studies using the outcome measures discussed above
(see Table 4). For each eligible study, a list was made in-
cluding the leading author, country and jurisdiction, de-
sign, sample, outcome measures, the PROs used, times
of feedback and intervention, members of medical teams
given feedback, management plans offered to teams, and
training (see Table 5). All qualifying studies were listed
chronologically with the outcome indicators (see
Table 3).
In Domain 1, the routinely collected PROs in particu-
lar participants or samples was classified as rated on a 4-
point scale representing how closely the participants or
samples overlapped with the characteristics and needs of
the intended study populations(1 star=very weakly re-
lated to 4 stars =very strong related). For example, for a
study conducted in the US on a sample of lung cancer
patients, the degree of overlap of the study sample with
the characteristics of lung cancer patients in the US over-
all was assessed by considering the study setting, sample
size and sampling frame, response rate, loss-to-follow-up,
and characteristics of the study sample. In Domain 2,
study design was classified and rated on 4 categories with
1 star indicating the weakest design and 4 stars indicatingthe strongest design. Four stars indicated a randomised
trial or experimental study; 3 stars indicated a controlled
trial, pre–post trial with control (controlled before–after
trial), time series, or observational cohort with multivari-
able adjustment; 2 stars indicated a pre–post trial without
control, observational cohort study without multivariable
adjustment, cross-sectional study without multivariable
adjustment, analysis of time trends without control, or
well-designed qualitative study; and 1 star indicated a case
series, other qualitative study, or survey (descriptive)
study.
Revised appraisal criteria were adapted from the guide-
lines on the assessment of quality improvement inter-
ventions [58,59]. A global rating was also created using
the Grading of Recommendations, Assessment, Develop-
ment, and Evaluation (GRADE) system [60]. The British
Medical Journal has recommended the GRADE system
since 2006 for grading evidence when submitting a clin-
ical guidelines article. It has multiple advantages and is
useful for systematic reviews and health technology as-
sessments, as well as for evaluating research on clinical
guidelines. The global rating created in the current study
was based on the integration of the Domain 1 and Do-
main 2 ratings, as well as the intervention fidelity (the
degree of success of the interventional strategy, the pa-
tients’ and providers’ adherence to the intervention strat-
egy), dose–response gradient, precision and validity of
outcomes (potential confounding factors and biases),
and uncertainty of the direction of results. The global
rating was divided into three categories; indication that
the study should carry great (3 checks), moderate (2
checks), or little (1 check) weight when considering the
strength of evidence (see Table 4). Any experimental re-
search that is reported in the manuscript was performed
with the approval of an appropriate ethics committee.
No attempt was made to quantitatively synthesize the re-
sults as the data were too heterogeneous to support pooling.
Results
The multi-method search strategy yielded 27 publica-
tions that were eligible to be included in the review – a
significant increase compared with most of the recent
reviews. The detailed flowchart of the search strategies
and its relative results was presented (Figure 3). The re-
sults and conclusions drawn were based on the 27 stud-
ies included in the analyses despite the large number of
full-text articles extracted.
Of the 27 publications, 16 were identified as randomised
controlled trials, 2 as before-after studies and 9 observa-
tional studies with 11 studies published before 2009. The
characteristics and quality of the studies are presented in
Table 5 with their impact on outcome indicators presented
in Table 3. As Trowbridge et al. (1997) was the only
article in the 1990s included in two of the previous



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SIRO Any visit Doctors and
nurses
(n=unreported)



































































































































































































































ESAS Every clinic visit Doctors and
nurses












































































































































































*: Four stars indicate a randomised trial or experimental study; 3 stars indicate a controlled trial, pre–post trial with control (controlled before–after trial), time ser s, or observational cohort with multivariable
adjustment; 2 stars indicate a pre–post trial without control, observational cohort study without multivariable adjustment, cross-sectional study without multivari le adjustment, analysis of time trends without control,
or well-designed qualitative study; and 1 star indicates a case series, other qualitative study, or survey (descriptive) study.
√: Three checks indicate great weight in the stratum’s body of evidence, 2 checks indicate moderate weight, and 1 check indicates little weight.
ǂ: EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life (EORTC QLQ) Core Questionnaire; SF-36: The Short Form(36) He h Survey; FACT-G: Functional Assessment of Cancer
Therapy-general; EORTC QLQ-BR23: EORTC QLQ Breast Cancer Scale; EORTC QLQ-CR38: EORTC QLQ Colorectal Cancer Scale; EORTC QLQ-LC; EORTC QLQ Lung Ca er Scale; NCI CATAE: National Cancer Institute
Common Terminology Criteria for Adverse Events; FACT-BCS: Functional Assessment for Cancer Therapy-Breast Cancer Subscale; FACT-C: Functional Assessment o Cancer Therapy-Colorectal Quality of Life Instrument;
FACT-L: Functional Assessment of Cancer Therapy-Lung Cancer Subscale; MOS-SS: Medical Outcomes Study Social Support Survey; GDS: Geriatric Depression Sc (short form); QARSQ-PH: Physical Health subscale of
the Older American Resources and Services Questionnaire (OARSQ); UMPSI: Utilisation of Mental Health and Psychosocial Services Instrument; GSRE: Geriatric Sch ule of Recent Experience Instrument;



























Table 4 The components, rating criteria and symbol, and categories used in summarising the study evidence in the
current study
Domain 1 Domain 2 Global (GRADE)
Decision
Components
Subject of public reporting (or
study population) and study
participants (sample)
Types of study (i.e. study designs) Components from Domain 1 & 2 as well as
implementation and adherence to intervention, dose–
response gradient, precision and validity of the
outcomes, uncertainty of direction of the results.
Rating criteria How well does the study sample
represent the study population?
How strong is the study design
both in terms of its external and
internal validity?
How much weight does the current study add to the





1*: no overlap 1*: weakest design √: little weight
2*: modest overlap 2*: moderate design √√: moderate weight
3*: large overlap 3*: strong design √√√: great weight
4*: complete overlap 4*: strongest design
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http://www.biomedcentral.com/1472-6963/13/211reviews, it was listed in the summation tables for the
purpose of comparison.
Overview of study quality
There has been a marked increase in the volume and
quality of the studies published recently in this area. Of
the 16 randomised controlled trials included in this re-
view, 7 were published between 2010 and 2011. The
quality of studies published since 2010 is also demon-
strably improved with much larger sample sizes, includ-
ing 3 trials [54,57,61] with a sample size greater than
200 and 2 trials with a sample size over 580 [51,56].
However, despite the increased volume and improved
quality of the studies, there remains a lack of large
cluster randomised controlled design studies, as
recommended by Fayers [62] who argues that cluster
RCTs are well suited to overcome the limitations of sim-
ple RCTs. It is well-known that system intervention tri-
als such as routine collection of PROs, and feedback to
the clinicians and systems, are prone to cross-
contamination and to introducing investigator and par-
ticipant biases. Two recently published studies [54,57]
were the continuation of an earlier study published by
Velikova et al. (2004) [36]. Most studies reviewed did
not systematically examine outcomes and mechanisms,
and placed more emphasis on processes rather than out-
come measures [25]. All studies were conducted in a
limited setting (often in a single centre) thus restricting
the generalisation of the findings.
No studies have adopted a comprehensive theoretical
model and framework, despite the repeated demand
from leading researchers in the area [25,63-65]. All stud-
ies focused on the patient and health professional level
within the clinic setting. No study to date has examined
the impact of collecting PROs on health care organisa-
tions, health system improvement, quality improvement
or population health at a system or societal level.Overview of study findings
Impact on patient-provider communication
Across the 27 studies included in this review, 4 studies
[39,47,51,53] did not examine or report the effect of a rou-
tinely collected PRO on patient-provider communication.
Among the 23 studies that did report such an impact, 21
studies (91.3%) reported a positive effect which included
well-designed and conducted large RCTs [33,36,37,54,56,57].
One study reported no significant improvement of patient-
provider communication possibly due to a lower severity
level of cancer patients (only 37% of patients received anti-
cancer therapy, hence the reduced need for communication
for the treatment) [38]. Another study reporting a negative
effect had an already high communication level at baseline
(hence a ceiling effect leaving little room for further
improvement) [34].
Impact on monitoring treatment response
Despite most of included 27 studies did not explicitly state
their study objectives as to examine the impact on moni-
toring treatment response, 11 of the 27 studies did report
an outcome (Table 3) [16,20,36,41,45-51]. All 11 studies
found a strong or modest effect of implementing PROs on
the increased monitoring activities of treatment response.
The strongest effect occurred in the studies that focused
on the monitoring of patient symptoms, side effects and
toxicity during and after chemotherapy for the outpatients.
In particular, the real-time, patient reported symptoms
and toxicity (through innovative mobile phone-based,
web-based or IVR systems) significantly improved the
monitoring of treatment response.
Impact on detecting unrecognised problems
Although the idea of routinely collected PROs may provide
better opportunities for services providers (as well as pa-
tients) to detect unrecognised problems through growing
awareness, improved communication and monitoring seems
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Table 5 The impact and effect sizes of the studies on patients, care providers and organisations* (Continued)
Korniblith et al.
(2006)[43]
+++ (both arms) ++ (more
from TM+EM
arm)
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Given et al.
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Mark et al.
(2008)[49]
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Kearney et al.
(2009)[50]





















































Table 5 The impact and effect sizes of the studies on patients, care providers and organisations* (Continued)
Ruland et al.
(2010)[53]
++ ++ ++ ++
Velikova et al.
(2010)[54]












et al. (2011) [55]
+ + + ++ + 89% of nurses and
55% of physicians
referred to the ESAS in

























Note: +++ very strong effect; ++ strong effect; + some effect; +/- uncertain effect; - No effect; blank : untested or reported;
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through other sources 
(n =182) 






Full-text articles assessed 
for eligibility  
(n =62) 
Full-text articles excluded, 
with reasons 
(n = 35) 
description of 
information technique 





not having sufficient 
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results related to the detection of unrecognised problems
(Table 3). Amongst the 16 studies, 15 studies [16,20,33,36,
37,39,41,43,45-50,53] reported either a strong or moderate
positive impact on detecting unrecognised problems. How-
ever, a study by McLachlan and colleagues [38] did not find
any difference between the intervention arm and control
arm.Impact on changes to patient health behaviour
No study to date has provided a systematic evaluation
on the impact of collecting PROs on changes to patient
health behaviour. It is unknown whether and how pa-
tient health behaviours have been changed.Impact on changes to patient management
Amongst 17 studies that provided some results of changes
to patient management, 13 studies [11,20,33,37,39,
45,46,48-50,52,53,55] reported either a strong or modest
positive effect on the changes to patient management
whilst 4 studies [34-36,54] found no such effect. However,
it is worth noting that 10 studies did not provide any infor-
mation about the changes to patient management andthere were often less complete descriptions of the results
on patient management when reported.Impact on patient satisfaction
Among the 16 studies that reported results related to
the impact on patient satisfaction, 13 studies [11,16,20,
37,41,43-46,48,49,52,54] reported a very strong to mod-
erate positive effect on improved patient satisfaction. For
the three studies [33,34,38] that did not find such a posi-
tive effect, one study [33] reported a possible ceiling ef-
fect meaning that both the intervention group and
control group had a very high baseline patient satisfac-
tion level potentially impeding any demonstration of a
significant difference between two arms during the
follow-up period.Impact on health outcomes
Amongst the 15 studies that reported some results re-
lated to the impact on health outcomes, 13 studies
[20,35-37,39,41-43,45,47,50,51,53] reported some posi-
tive improvement, ranging from modest to strong, while
two studies [34,38] failed to find any such effect. It ap-
pears that symptoms, side effects and toxicity are most
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There is little evidence on the improvement of both
overall HRQOLs as well as social wellbeing.
Impact on quality improvement, transparency, accountability
and public reporting, and on better system performances
(monitoring, planning, financing, evaluating, responding)
No study to date has provided a meaningful, explicit
framework nor relevant evidence on these endpoints.
Overall strength and direction of evidence
Overall, there is strong evidence supporting the notion
that routinely collected PROs, with feedback, improves
patient-provider communication and increases patient
satisfaction (Table 6). There is some evidence to support
the notion that it improves the monitoring of treatment
responses and detection of unrecognised problems, and
there is weak but positive evidence that, over time, it
leads to changes in patient management. Despite some
encouraging results, there is still a great degree of uncer-
tainty regarding the impact of routinely collected PROs,
with feedback, on patient health outcomes. There is little
or no evidence that it has led to significant positive im-
provements in quality improvement, transparency, ac-
countability, and public reporting, or in system
performance at a population health or societal level.
Apart from clinical trials and clinical practice, its impact
on health services research and population health is
largely unknown.
Potential moderating factors and links between routine
PRO collection (with feedback) and patient outcomes
Although the evidence is limited, it appears that routine
collected PROs with sufficient intensity of feedback




Monitor treatment response ++
Detect unrecognised problems ++
Changes to patient health behaviour n/a
Changes to patient management +
Improved patient satisfaction +++
Improved health outcomes +/0
Strong & effective quality improvement n/a
Increased transparency, accountability, public
reporting
n/a
Better system performance (monitoring,
planning, financing, evaluating, responding)
n/a
Note: ++++: the strongest positive effect; xxxx: the strongest negative effect;
n/a: not available; 0: mutual (no significant effect).[13,39,44,54], targeting multiple stakeholders (doctors,
nurses, allied health workers, as well as patients) [35,52]
with simple, clear, graphical and longitudinal meaningful
interpretation of the results, and providing sufficient
training for both health professionals and patients
[20,57], are critical links between an intervention and
the intended outcomes. There is also evidence to suggest
that for some complex issues such as depression and
low social functioning, routine screening and feedback
may need to be integrated with other strategies such as
decision-making aids, education, clear management
plans and clinical pathways including referrals, in order
to change patient outcomes [43,49,51]. There is prelim-
inary evidence that some of the impacts of PROs may be
more pronounced amongst subgroups with more severe
problems at baseline (e.g. depression, symptoms)
[38,42,65]. More studies are needed to fully understand-
ing these mediating and moderating effects.
Discussion
There is very strong evidence in supporting the notion
that routine collected PROs with timely feedback en-
hances patient-provider communication. This current
study finding of a positive effect on patient-provider
communication is consistent with previous reviews
conducted in both cancer [26] and non-cancer settings
[25,27,28]. There is also strong evidence to support the
notation that routine collected PROs significantly im-
proved the monitoring of treatment response.
There is reasonably strong evidence in supporting the
notation that routine collected PROs are helpful in identi-
fying unrecognised problems in a large variety of settings.
Within studies that reported, to some extent, the results
related to unrecognised problems, there is a need for the
development of more comprehensive and valid measures.
Such a change in the measures would contribute towards
understanding specifically the PROs’ impact on identifying
the underreported and unrecognised problems for differ-
ent cancer patients at different settings.
Overall, there is reasonable evidence in favouring the
hypothesis that implementing a routine collected PROs
system brings positive changes to patient management in
the settings where a patient management plan is inte-
grated with a routine collection of PROs. It appears that
the simple routine feedback of PROs may not be sufficient
to improve patient management and outcomes [48]. Other
necessary resources may be needed such as education, re-
ferral services and a detailed patient management plan fol-
lowing the PROs [43]. There is also a need to develop
better measures of change to patient management as it is
often complex and difficult to quantify [57].
There is strong evidence to support the notation that
routine collected PROs with timely feedback significantly
enhance patient’s experience and satisfaction. There may
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stakeholders such as patients’ family members, caregivers,
as well as health professionals that were not measured or
unreported. Future research into furthering the under-
standing of stakeholder experience after implementing
routine collected PROs would be desirable.
Although positive evidence in supporting the notion
that routine collected PROs may improve health out-
comes is weak, this finding needs to be confirmed by
better designed studies covering a large set of well-
developed outcome measures. There is also a need to
understand the impact on long-term health outcomes
such as survival rate. Most of the studies included in this
review did not focus on health outcomes and some of
the positive improvement on the outcomes only oc-
curred on selective measures. It is not clear how these
positive improvements can be generalised across differ-
ent settings.
There is a variety of models on how to routinely col-
lect PROs and how to feed back the data to different
stakeholders. Given that cancer patients are vastly differ-
ent given their background, type and stage of cancer,
prognosis, treatment, and the positions at the life course
continuum, precaution should be exercised when
attempting to apply the general observation above to
each and every different setting. For example, recent
studies demonstrated a positive impact of routine col-
lected PROs on symptom control through either web-
based or mobile phone based approach. However, such
positive impacts were less pronounced on HRQOL.
Limitations of the current review
Our review has several limitations. First, there was no
attempt made to contact the authors to ask for potential
unpublished data on the topic. Thus, there may be
chance of missing some grey literature or the studies
that under preparation for publication. Second, given the
multitude of endpoints included, and different types of
studies involved, the assessment of eligibility for inclu-
sion of potential studies required some degree of sub-
jective judgement. Third, our application of GRADE
system was rather simplistic restricted by large number
of endpoints and variability of studies included. These
limitations may give rise to some uncertainty in terms of
synthesis of the results. Fourth, our study follows a sys-
tematic review approach with inclusion of both experi-
mental trials and quantitative observational studies.
However, we did not include qualitative studies in our
review which may provide additional insight into the
questions raised. This is particularly relevant with re-
spect to questions 2 and 3 as there was very little quanti-
tative evidence from the included studies. It is important
to note that despite efforts to formulate the review end-
points based on solid and well-established causal andtheoretical frameworks (providing insight into not only
if but also how the introduction of PROs affects patient
outcomes), the causal mechanisms and process end-
points included in the current review are by no means
exhaustive. There may be other important causal mecha-
nisms that could be benefited from a realist review ap-
proach [66].
Conclusions
There is growing evidence supporting the routine collec-
tion of PRO to enable better and patient-centred care,
especially in cancer settings. Despite the strong evidence
in supporting the notion that the well-implemented rou-
tine collection of PROs enhances patient-provider com-
munication and improves patient satisfaction, and
growing evidence supporting ideas that it also improves
the monitoring of treatment response and the detection
of the unrecognised problems, the evidence-base was
weak for its impact on changes to patient management
and improved health outcomes and non-existent for
changes to patient health behaviour, strong and effective
quality improvement, increased transparency, account-
ability, public reporting and better health care system
performance. These evidence gaps require further com-
mitted and well-planned research in addition to the
well-accepted PROs. Decision-making agencies have
been well positioned for leverage on the rapid advance-
ment of different PRO models, the application of the
item response theory and computer adapted test in de-
veloping PROs, and on the acceptance of such technol-
ogy by patients and health professionals over the last
decade. The real-time and routinely collected PROs will
enable the development of a rapid learning health sys-
tem with the potential to advance our knowledge of drug
development, unsurpassed models of cancer patient care
and a more patient-centred health care system.
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